BR0008382A - Formulação de liberação controlada para tratamento de copd - Google Patents

Formulação de liberação controlada para tratamento de copd

Info

Publication number
BR0008382A
BR0008382A BR0008382-8A BR0008382A BR0008382A BR 0008382 A BR0008382 A BR 0008382A BR 0008382 A BR0008382 A BR 0008382A BR 0008382 A BR0008382 A BR 0008382A
Authority
BR
Brazil
Prior art keywords
controlled release
release formulation
copd
copd treatment
treatment
Prior art date
Application number
BR0008382-8A
Other languages
English (en)
Inventor
Patrick G Faulkner
Jaime J Lucca
Thomas J Wrzosek
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of BR0008382A publication Critical patent/BR0008382A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"FORMULAçãO DE LIBERAçãO CONTROLADA PARA TRATAMENTO DE COPD". A invenção refere-se a uma formulação de liberação controlada ou prolongada destinada a liberar um inibidor de PDE4 para tratamento de uma doença inflamatória como asma ou COPD e similar.
BR0008382-8A 1999-02-23 2000-02-22 Formulação de liberação controlada para tratamento de copd BR0008382A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12129199P 1999-02-23 1999-02-23
PCT/US2000/004713 WO2000050011A1 (en) 1999-02-23 2000-02-22 Controlled release formulation for treating copd

Publications (1)

Publication Number Publication Date
BR0008382A true BR0008382A (pt) 2002-02-05

Family

ID=22395738

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0008382-8A BR0008382A (pt) 1999-02-23 2000-02-22 Formulação de liberação controlada para tratamento de copd

Country Status (29)

Country Link
US (1) US20030211152A1 (pt)
EP (1) EP1154758A4 (pt)
JP (1) JP2002537320A (pt)
KR (1) KR20010112279A (pt)
CN (1) CN1195496C (pt)
AR (1) AR028986A1 (pt)
AU (1) AU3501500A (pt)
BG (1) BG105905A (pt)
BR (1) BR0008382A (pt)
CA (1) CA2366747A1 (pt)
CO (1) CO5150233A1 (pt)
CZ (1) CZ20013025A3 (pt)
EA (1) EA200100906A1 (pt)
HK (1) HK1043045A1 (pt)
HU (1) HUP0200134A3 (pt)
ID (1) ID29792A (pt)
IL (1) IL144603A0 (pt)
MA (1) MA25386A1 (pt)
MY (1) MY121142A (pt)
NO (1) NO20014049L (pt)
NZ (1) NZ527716A (pt)
OA (1) OA11836A (pt)
PE (1) PE20001496A1 (pt)
PL (1) PL350287A1 (pt)
SK (1) SK12072001A3 (pt)
TR (1) TR200102448T2 (pt)
TW (1) TWI224013B (pt)
WO (1) WO2000050011A1 (pt)
ZA (1) ZA200106803B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0203682A3 (en) * 1999-10-29 2003-10-28 Smithkline Beecham Plc Method for administering a phosphodiesterase 4 inhibitor
KR20040007596A (ko) * 2001-05-23 2004-01-24 다나베 세이야꾸 가부시키가이샤 골절 치료 촉진용 조성물
JP4510383B2 (ja) * 2001-05-23 2010-07-21 田辺三菱製薬株式会社 軟骨疾患修復治療用組成物
NZ532279A (en) * 2001-09-19 2006-02-24 Altana Pharma Ag Combination of a PDE inhibitor and a leukotriene receptor antagonist
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
WO2005030178A1 (en) * 2003-09-30 2005-04-07 Lupin Ltd. Extended release formulation of beta-lactam antibiotics
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
MX2007001706A (es) * 2004-08-13 2007-04-12 Boehringer Ingelheim Int Formulacion de comprimidos de liberacion extendida que contiene pramipexol o una sal farmaceuticamente aceptable del mismo, metodo para su fabricacion y su uso.
GB0511066D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
CN109908139B (zh) * 2018-12-28 2022-02-22 南京市儿童医院 西洛司特在制备用于治疗急性肾损伤相关病症的药物中的用途
PL3911304T3 (pl) * 2019-01-15 2023-12-04 UNION therapeutics A/S Preparat w postaci tabletek o zmodyfikowanym uwalnianiu, zawierający inhibitory fosfodiesterazy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL297088A (pt) * 1961-01-31
IL78017A (en) * 1986-03-03 1989-06-30 Yissum Res Dev Co Sustained release tablets of theophylline
US5286494A (en) * 1986-07-02 1994-02-15 Schering Aktiengesellschaft Medicinal agents with sustained action
WO1993019749A1 (en) * 1992-04-02 1993-10-14 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
GB9222253D0 (en) * 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
US5672622A (en) * 1994-04-21 1997-09-30 Berlex Laboratories, Inc. Treatment of multiple sclerosis
US5998428A (en) * 1995-05-31 1999-12-07 Smithkline Beecham Corporation Compounds and methods for treating PDE IV-related diseases
US6210710B1 (en) * 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
US5840329A (en) * 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
AR035987A1 (es) * 1999-03-01 2004-08-04 Smithkline Beecham Corp Uso de un compuesto inhibidor de la pde 4 para la manufactura de un medicamento y el medicamento para tratar asma inducida por ejercicio

Also Published As

Publication number Publication date
IL144603A0 (en) 2002-05-23
HK1043045A1 (zh) 2002-09-06
EP1154758A4 (en) 2007-09-05
SK12072001A3 (sk) 2002-01-07
PL350287A1 (en) 2002-12-02
US20030211152A1 (en) 2003-11-13
CN1347314A (zh) 2002-05-01
NZ527716A (en) 2005-03-24
MA25386A1 (fr) 2002-04-01
HUP0200134A2 (hu) 2002-05-29
CO5150233A1 (es) 2002-04-29
WO2000050011A1 (en) 2000-08-31
EA200100906A1 (ru) 2002-02-28
OA11836A (en) 2005-08-22
BG105905A (bg) 2002-04-30
CN1195496C (zh) 2005-04-06
TR200102448T2 (tr) 2003-03-21
TWI224013B (en) 2004-11-21
KR20010112279A (ko) 2001-12-20
CZ20013025A3 (cs) 2002-07-17
ID29792A (id) 2001-10-11
NO20014049D0 (no) 2001-08-20
CA2366747A1 (en) 2000-08-31
AR028986A1 (es) 2003-06-04
JP2002537320A (ja) 2002-11-05
ZA200106803B (en) 2002-08-19
PE20001496A1 (es) 2001-02-08
HUP0200134A3 (en) 2003-03-28
NO20014049L (no) 2001-10-22
MY121142A (en) 2005-12-30
AU3501500A (en) 2000-09-14
EP1154758A1 (en) 2001-11-21

Similar Documents

Publication Publication Date Title
NO20034056D0 (no) Proliferative sykdommer
WO2001064214A3 (en) Compositions and methods for the treatment of inflammatory diseases using topoisomerase inhibitors
WO1998056771A3 (en) Piperazine derivatives and their use as anti-inflammatory agents
MEP90508A (en) New pharmaceutical composition
WO2005004803A3 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
WO2004062625A3 (en) Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease
WO1999062510A3 (en) Compositions comprising anti-microtubule agents for treating or preventing inflammatory diseases
DE60239648D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Asthma
WO2005032471A3 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
WO1999063999A8 (en) H1-histamine receptor antagonists
ECSP045520A (es) Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos
BR0011448A (pt) Imidazoquinolinas substituìdas por amida
WO2004045592A3 (en) Compounds and methods for increasing neurogenesis
WO2005065195A3 (en) Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease
MXPA00011422A (es) Derivados de bencimidazol como moduladores de ige.
WO2005004802A3 (en) N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease
BR0104654A (pt) Artigo absorvente
PL362477A1 (en) Hmg-coa reductase inhibitors and their use as medicaments for the treatment of cholesterol related diseases
BR0008382A (pt) Formulação de liberação controlada para tratamento de copd
WO2003072593A3 (en) Bone targeting peptides
BR0318278A (pt) compostos de éter aminocicloexìlico e usos dos mesmo
WO2003065987A3 (en) Granzyme b inhibitors
DE60141636D1 (de) Phospholipidderivate von valproinsäure und ihre kombinationen
WO2002068476A3 (en) Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders
BR9809848A (pt) Composição

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A E 9A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 NA RPI2003 DE 26/05/2009.